Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELL | P14151 | 2/20 | 0.62 |
| ▸ | SELP | P16109 | 2/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.61 |
| ▸ | HTR7 | P34969 | 5/20 | 0.61 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.56 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
| ▸ | CTSA | P10619 | 2/20 | 0.49 |
| ▸ | SELE | P16581 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7031826 | 0.87 | HTR7 (0.63) | SELLSELPFFAR1HTR7PTGER1 | |
| SCHEMBL21368940 | 0.87 | HTR7 (0.59) | SELLSELPFFAR1HTR7PTPN5 | |
| SCHEMBL3670702 | 0.86 | FFAR1 (0.76) | FFAR1HTR7PTGER1PTGER4PTGER3 | |
| SCHEMBL4172402 | 0.85 | CYP1A1 (0.63) | SELLSELPFFAR1GAAALDH1A1 | |
| SCHEMBL17187933 | 0.84 | PLA2G10 (0.60) | SELLSELPFFAR1PTGER1PTGER4 | |
| SCHEMBL2592720 | 0.83 | HTR7 (0.56) | SELLSELPFFAR1HTR7PTPN5 | |
| SCHEMBL4207640 | 0.83 | SLC13A5 (0.60) | FFAR1PTGER4GAAALDH1A1TSHR | |
| SCHEMBL3839813 | 0.82 | PLA2G10 (0.58) | SELLSELPPTGER1PTGER4PTGER3 | |
| SCHEMBL20519924 | 0.82 | GAA (0.62) | SELLSELPGAAALDH1A1TSHR | |
| SCHEMBL28454360 | 0.82 | GAA (0.62) | SELLSELPGAAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566580-A1 | PROCESS FOR THE PREPARATION OF BIMOSIAMOSE | Revotar Biopharmaceuticals AG (DE) | 2013-03-13 | — | — | EP | claimed |
| WO-2011138365-A1 | PROCESS FOR THE PREPARATION OF BIMOSIAMOSE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-11-10 | — | — | WO | claimed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| CN-103002951-A | Process for the preparation of new compound | REVOTAR BIOPHARMACEUTICALS AG | 2013-03-27 | — | — | CN | disclosed |
| EP-2566580-A1 | PROCESS FOR THE PREPARATION OF BIMOSIAMOSE | Revotar Biopharmaceuticals AG (DE) | 2013-03-13 | — | — | EP | disclosed |
| EP-2566580-A1 | PROCESS FOR THE PREPARATION OF BIMOSIAMOSE | Revotar Biopharmaceuticals AG (DE) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011138365-A1 | PROCESS FOR THE PREPARATION OF BIMOSIAMOSE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011138365-A1 | PROCESS FOR THE PREPARATION OF BIMOSIAMOSE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-11-10 | — | — | WO | disclosed |
| US-5444050-A | Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1995-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | SELL 3703/4885SELP 3242/4885FFAR1 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.